Viridian Therapeutics, Inc.\DE
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
221 CRESCENT STREET, WALTHAM, MA, 02453
Mailing Address
221 CRESCENT STREET, WALTHAM, MA, 02453
Phone
617.272.4600
Fiscal Year End
1231
EIN
471187261
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 4, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Accelerated R&D with lead programs VRDN-123 (Phase 2b enrollment completed) and VRDN-456 (Phase 1 initiated).
- Collaboration revenue increased to $15 million, validating the company's platform technology.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.